adult population now 75% overweight or obese, according to The New York Times , the urgency for effective interventions has never been greater
2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events A 2024 Meta-analysis of 13 multiple cardiovascular outcome trials has documented that GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis
Managing ozempic and hashimoto needs a team effort
With so many bottles promising to "boost metabolism" or "support thyroid health," it is difficult to know which ones are backed by science and which might actually do more harm than good